PL3055333T4 - Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii - Google Patents
Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemiiInfo
- Publication number
- PL3055333T4 PL3055333T4 PL14802527T PL14802527T PL3055333T4 PL 3055333 T4 PL3055333 T4 PL 3055333T4 PL 14802527 T PL14802527 T PL 14802527T PL 14802527 T PL14802527 T PL 14802527T PL 3055333 T4 PL3055333 T4 PL 3055333T4
- Authority
- PL
- Poland
- Prior art keywords
- pcsk9 inhibitor
- treat hyperlipidemia
- hyperlipidemia
- treat
- pcsk9
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890154P | 2013-10-11 | 2013-10-11 | |
| US201461923103P | 2014-01-02 | 2014-01-02 | |
| US201461955514P | 2014-03-19 | 2014-03-19 | |
| US201462004620P | 2014-05-29 | 2014-05-29 | |
| US201462025104P | 2014-07-16 | 2014-07-16 | |
| EP14306221 | 2014-07-31 | ||
| US201462054571P | 2014-09-24 | 2014-09-24 | |
| EP14306584 | 2014-10-09 | ||
| PCT/US2014/060109 WO2015054619A2 (en) | 2013-10-11 | 2014-10-10 | Use of a pcsk9 inhibitor to treat hyperlipidemia |
| EP14802527.3A EP3055333B1 (en) | 2013-10-11 | 2014-10-10 | Use of a pcsk9 inhibitor to treat hyperlipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3055333T3 PL3055333T3 (pl) | 2020-06-01 |
| PL3055333T4 true PL3055333T4 (pl) | 2020-07-27 |
Family
ID=52813751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19210918T PL3689913T3 (pl) | 2013-10-11 | 2014-10-10 | Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii |
| PL14802527T PL3055333T4 (pl) | 2013-10-11 | 2014-10-10 | Wykorzystanie inhibitora pcsk9 do leczenia hyperlipidemii |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19210918T PL3689913T3 (pl) | 2013-10-11 | 2014-10-10 | Zastosowanie inhibitora PCSK9 do leczenia hiperlipidemii |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150140002A1 (pl) |
| EP (2) | EP3689913B1 (pl) |
| JP (2) | JP6846931B2 (pl) |
| KR (3) | KR20160062166A (pl) |
| CN (3) | CN115192704A (pl) |
| AU (2) | AU2014331754B2 (pl) |
| CA (1) | CA2926942A1 (pl) |
| EA (1) | EA037526B1 (pl) |
| ES (1) | ES2914978T3 (pl) |
| IL (1) | IL244995B (pl) |
| MX (3) | MX2016004580A (pl) |
| PL (2) | PL3689913T3 (pl) |
| TW (1) | TWI669131B (pl) |
| WO (1) | WO2015054619A2 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| KR20200133826A (ko) | 2011-01-28 | 2020-11-30 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA028278B1 (ru) | 2011-09-16 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9) |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EA201592267A1 (ru) | 2013-06-07 | 2016-04-29 | Ридженерон Фармасьютикалз, Инк. | Способы ингибирования атеросклероза посредством введения ингибитора pcsk9 |
| CN118105481A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| CA2954767A1 (en) * | 2014-07-14 | 2016-01-21 | Amgen Inc. | Crystalline antibody formulations |
| CN107206068A (zh) | 2014-07-16 | 2017-09-26 | 赛诺菲生物技术公司 | 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法 |
| EP3283012A4 (en) * | 2015-04-15 | 2018-11-21 | Concievalve LLC | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
| CN104861071B (zh) * | 2015-04-27 | 2019-04-12 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
| WO2017031151A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| KR20190049866A (ko) | 2016-09-20 | 2019-05-09 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-ｐｃｓｋ９ 항체 |
| KR102401796B1 (ko) | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
| WO2018200489A1 (en) | 2017-04-25 | 2018-11-01 | The Brigham And Women’S Hospital, Inc. | Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis |
| CN107090474A (zh) * | 2017-05-22 | 2017-08-25 | 山东大学 | 一种腹主动脉瘤疾病动物模型的制备方法 |
| CN109963877B (zh) * | 2017-06-14 | 2023-01-20 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| CA3092936A1 (en) * | 2018-03-06 | 2019-09-12 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
| CA3125765A1 (en) | 2019-01-18 | 2020-07-23 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| JP2023501745A (ja) * | 2019-11-18 | 2023-01-18 | エーディー ファーマシューティカルズ カンパニー，リミティド | 抗ｐｃｓｋ９抗体及びその使用 |
| AU2020402044A1 (en) * | 2019-12-10 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Use of a PCSK9 inhibitor to treat homozygous familial hypercholesterolemia |
| CN114277032A (zh) * | 2021-12-31 | 2022-04-05 | 华中科技大学同济医学院附属协和医院 | 一种低密度脂蛋白受体基因突变体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8357371B2 (en) * | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| KR20200133826A (ko) * | 2011-01-28 | 2020-11-30 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA028278B1 (ru) * | 2011-09-16 | 2017-10-31 | Ридженерон Фармасьютикалз, Инк. | СПОСОБЫ СНИЖЕНИЯ УРОВНЕЙ ЛИПОПРОТЕИНА(а) ПОСРЕДСТВОМ ВВЕДЕНИЯ ИНГИБИТОРА ПРОПРОТЕИНКОНВЕРТАЗЫ СУБТИЛИЗИН/КЕКСИН-9 (PCSK9) |
| TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
-
2014
- 2014-10-10 ES ES19210918T patent/ES2914978T3/es active Active
- 2014-10-10 WO PCT/US2014/060109 patent/WO2015054619A2/en active Application Filing
- 2014-10-10 CN CN202210762455.1A patent/CN115192704A/zh active Pending
- 2014-10-10 EP EP19210918.9A patent/EP3689913B1/en active Active
- 2014-10-10 EA EA201690754A patent/EA037526B1/ru unknown
- 2014-10-10 PL PL19210918T patent/PL3689913T3/pl unknown
- 2014-10-10 AU AU2014331754A patent/AU2014331754B2/en active Active
- 2014-10-10 CN CN202210729601.0A patent/CN115154599A/zh active Pending
- 2014-10-10 MX MX2016004580A patent/MX2016004580A/es active IP Right Grant
- 2014-10-10 KR KR1020167012099A patent/KR20160062166A/ko not_active IP Right Cessation
- 2014-10-10 CA CA2926942A patent/CA2926942A1/en active Pending
- 2014-10-10 KR KR1020227011822A patent/KR20220048051A/ko not_active Application Discontinuation
- 2014-10-10 CN CN201480066894.2A patent/CN105814085A/zh active Pending
- 2014-10-10 US US14/511,975 patent/US20150140002A1/en not_active Abandoned
- 2014-10-10 PL PL14802527T patent/PL3055333T4/pl unknown
- 2014-10-10 JP JP2016521604A patent/JP6846931B2/ja active Active
- 2014-10-10 EP EP14802527.3A patent/EP3055333B1/en active Active
- 2014-10-10 KR KR1020237026483A patent/KR20230119045A/ko not_active Application Discontinuation
- 2014-10-13 TW TW103135495A patent/TWI669131B/zh active
-
2016
- 2016-04-08 MX MX2022013172A patent/MX2022013172A/es unknown
- 2016-04-08 MX MX2020004023A patent/MX2020004023A/es unknown
- 2016-04-10 IL IL244995A patent/IL244995B/en active IP Right Grant
-
2019
- 2019-08-09 JP JP2019146940A patent/JP6994484B2/ja active Active
-
2020
- 2020-06-02 AU AU2020203636A patent/AU2020203636B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244995A0 (en) | Using pcsk9 inhibitor to treat hyperlipidemia | |
| IL279682A (en) | Benzoquinolone compounds as VMAT2 inhibitors | |
| HUE061252T2 (hu) | Lizinspecifikus demetiláz-1 inhibítorok | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| HK1223926A1 (zh) | 用於製備 抑制劑的方法 | |
| ZA201702252B (en) | A selective inhibitor of prosphatidylinositol 3-kinase-gamma | |
| EP2958964A4 (en) | TREATMENT OF FREQUENTLY AFFECTED SURFACES TO IMPROVE HYGIENE | |
| HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
| EP3632467C0 (en) | INHIBITORS OF COMPLEMENT FACTOR H | |
| HK1221645A1 (zh) | 的苯並喹啉抑制劑 | |
| ZA202207530B (en) | Use of phenoxypropylamine compounds to treat depression | |
| IL240763A0 (en) | The halopyrazoles as thrombin inhibitors | |
| DK2928477T3 (da) | Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis | |
| ZA201409181B (en) | Treatment of waste water | |
| PL2888228T3 (pl) | Inhibitory oddziaływania CD40-TRAF6 | |
| PT3055333T (pt) | Uso de um inibidor de pcsk9 para tratar a hiperlipidemia | |
| PT3689913T (pt) | Uso de um inibidor de pcsk9 para tratar a hiperlipidemia | |
| ZA201409002B (en) | Treatment of waste water | |
| GB201308117D0 (en) | Inhibitor of calcifying disorders | |
| GB201322036D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201310488D0 (en) | New therapeutic uses of enzyme inhibitors |